Abstract 56P
Background
The incidence of colorectal cancer (CRC) has increased among the younger population. Adolescents and young adults (AYA) are an important component of the active population in any country that impact the health care system along with socio-economic consequences. We present one of the first multicentre collaborative studies on AYA CRC from a low and middle-income country (LMIC).
Methods
The study was a multicentre retrospective registry conducted over the period of 3 years, from January 2018 to December 2020, after approval from respective IECs. A total of 126 AYA CRC Patients were enrolled in the study. The details regarding socio-demographic profile, histopathology, and therapeutic details were recorded.
Results
A total of 126 patients of AYA colorectal cancer patients were enrolled in the study between 2018 - 2020. 62.70% of patients had colon cancer, 37.30 % had rectal cancer. 50.79 % of patients were male. 67.46% of patients belong to 31-40 age group, with an average age of 32.6 years. Abdomen pain and distension (34%), and blood in stools (22%) were the most common presentations. On presentation, 31.75% had cTNM stage IV, 28.57% stage III, 15.87% stage II as per AJCC 8. 92(74.60%) underwent surgery, and adenocarcinoma (65.08 %) was the most common histology. 28.57% of patients were stage III on pTNM. Most of the patients were offered potentially curative therapy (65.87%), and 33.33% of patients were on palliative treatment. CAPOX was the most commonly prescribed chemotherapy regimen. MSI profiling was available only for eight patients.
Conclusions
As per our knowledge, this study is one of the first multicentre collaborative studies from an LMIC related to the clinic-pathological profile of AYA CRC patients. Most such patients present in non-metastatic stage, and potentially receive curative therapy. However, only a small minority could get MSI/mutational profiling.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Biotechnology Industry Research Assistance Council (BIRAC) India.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
79P - Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase III HIMALAYA study
Presenter: Arndt Vogel
Session: Poster viewing 02
82P - A randomized controlled, open-label, adaptive phase III clinical trial to evaluate safety and efficacy of EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas after FOLFIRINOX
Presenter: Muh-Hwan Su
Session: Poster viewing 02
83P - Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster viewing 02
84P - Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population
Presenter: Margherita Rimini
Session: Poster viewing 02
86P - Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Presenter: Aiwu Ruth He
Session: Poster viewing 02
87P - Socio-demographic disparities in esophageal cancer: A SEER analysis
Presenter: Beas Siromoni
Session: Poster viewing 02
88P - Sintilimab plus anlotinib as second-line therapy for metastatic or recurrent gallbladder carcinoma (GBC): A single-arm, phase II study
Presenter: Qingbao Cheng
Session: Poster viewing 02